All investors in the panel “Biotech Funding: Navigating Challenges, Exploring Solutions” at #KnowledgeforGrowth today agreed that the craziness on the biotech capital market might be over, but that this is actual a good thing because the focus is again on substance, on matter not on hype. Christina Takke, Katrien Swerts, Jan Van den Bossche, Richard Reschen, Servaas Michielssens, PhD, CFA were the panelists and Bram Van Parys was the moderator of this session. Companies with good data will get good funding, according to the investors. And if a company can reach milestones without spending too much money, even better. This shows that the company is well organized and can manage its projects well. In Europe companies need to work on shoestring budgets more often, compared to the US, but they are also usually better at it. This is a good thing because most investors want efficient use of cash according to the speakers. And pressure on the budget often also results in smart, creative solutions. The next big think the panelists are keeping a close eye on are the technical fields of obesity, metabolism, siRNA’s, especially in neurobiology in the field of Alzheimer’s and ALS. Further, new biomarkers allow more effective clinical testing, which already resulted for example in the recent amyloid approvals. Precision fermentation, cell free fermentation with increased carbon utilization as an advantage, and capturing CO2, and growing bacteria on CO2 only are also promising fields, as are therapies in oncology brought to other fields such as immunology, as well as AI in health tech and drug development, which is expected to increase speed, reduce costs, and result in better products.
Emma Wong Fong Sang’s Post
More Relevant Posts
-
🚀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗻𝗴 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗟𝗮𝗯 𝘁𝗼 𝘁𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰 🚀 Exciting day at the 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗼𝗿𝘀’ 𝗗𝗮𝘆 𝟮𝟬𝟮𝟰, organized by the BioRN Life Science Cluster Rhine-Neckar. Our colleagues Barbara Eberbach and Dr. Christoph Schröder just pitched our 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 - a precise diagnostic test for 𝗔𝗰𝘂𝘁𝗲 𝗞𝗶𝗱𝗻𝗲𝘆 𝗜𝗻𝗷𝘂𝗿𝘆 (𝗔𝗞𝗜) that will detect this common complication 𝘁𝘄𝗼 𝗱𝗮𝘆𝘀 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 than the current clinical gold standard. 👩🔬 👨🔬 The development of this diagnostic test is based on biomarkers identified through our scioDiscover platform, demonstrating the successful translation of microarray-based research into clinical application. We are actively seeking 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 to bring this innovative test to market and make a real difference in patient outcomes. Let's push innovation forward! 🤝 #LifeScience #Diagnostics #AcuteKidneyInjury #AKI #Sciomics #Innovation #InvestInHealth #BioRN #Biomarkers #EarlyDetection
-
-
🚀 Driving Innovation with EIC Pathfinder Grant! We are thrilled to announce that our project, ISOS, has been awarded by the European Commission under grant agreement No. 101130454! 🎉 ISOS Project EU aims to revolutionise chronic disease treatment by developing the first biomedical product capable of in-situ fabrication and auto-renewed delivery of therapeutic compounds. Using complex ecosystems of genetically engineered bacteria within a biomaterial-based bioreactor, ISOS will produce therapeutic molecules "on demand", responding directly to the patient's pathological environment. This innovative approach will personalise treatment for conditions like age-related macular degeneration, potentially replacing repeated intraocular injections with a single implantable bioreactor. This groundbreaking project could pave the way for a new generation of therapeutic products, offering personalised treatments with rigorous control of drug production and delivery. We look forward to working with our incredible consortium partners (Silk Biomed SL (Silk), Universidad Complutense de Madrid, Leipzig University, Fraunhofer IZI, Alien Technology Transfer, Northumbria University) to drive this innovation and make a lasting impact on healthcare! 🌍 🔬 💡 🔗 Learn more about the project by visiting our ISOS website, and follow us on LinkedIn and X. https://lnkd.in/eaKgVRQj #EuropeanCommission #EUFunding #HorizonEurope #EIC #PathFinder #ResearchAndInnovation #ISOS #Innovation #BiomedicalResearch #ChronicDiseaseTreatment
-
Prenetics Global Limited (NASDAQ: PRE), a genomics-driven health sciences company, is making waves in the industry. With its three primary units – CircleDNA, Insighta, and ACT Genomics – PRE is advancing personalized medicine, early cancer detection, and genomic profiling for personalized cancer treatments. In the first quarter of 2024, PRE reported impressive financial results, including a 30.2% increase in revenue and a 159.8% surge in gross profit compared to the previous year. The company's strategic focus on the US consumer healthcare market aims to broaden accessibility to its science-based solutions. 'The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt, supported by a resilient and talented team,' said Danny Yeung, Chief Executive Officer and Co-Founder of PRE. PRE recently announced a partnership with former international footballer David Beckham, who has become a strategic investor and co-founding partner of a new health and wellness brand, IM8. 'This partnership with David marks a transformative era for PRE in global health innovation and wellness,' Yeung stated. With its innovative approach, strong financial performance, and high-profile collaborations, Prenetics Global Limited is poised to drive significant advancements in genomics and consumer health. #genomics #personalizedmedicine #cancerdetection #healthinnovation
Prenetics Global: Pioneering Genomics and Health Innovation with David Beckham
newsramp.com
-
We are thrilled to announce that AmiLyfe BioScience has acquired the assets of Entrinsic Bioscience, a strategic move that significantly enhances our capabilities and broadens our product portfolio. This acquisition includes rights to over 180 patents and trademarks, the renowned enterade® brand, and all existing licenses and product lines, establishing a robust technology platform fueled by our expertise in biomapping and electrophysiology. Key Highlights: Advanced Technology: With the integration of Entrinsic Bioscience’s assets, we now possess a powerful arsenal of IP and product lines, enhancing our innovative capabilities. Maestro™ AI Platform: Our proprietary AI platform, Maestro™, accelerates research into the cellular dynamics of natural amino acids, revealing their impact on crucial physiological functions. Expanded Product Line: We’ve identified over 50 biofunctional formulations targeting gut health, hydration, respiratory disease, and skincare, all clinically proven to provide significant health benefits. Innovative Solutions: Our flagship product, enterade oncology®, is a pioneering medical food that reduces the side effects of chemotherapy, radiation, and immunotherapy, benefiting patients in over 700 cancer centers worldwide. "AmiLyfe is here to revolutionize healthcare by blending biology and nature to elevate wellness from within." - Stephen Gatto, Chairman and CEO From protecting astronauts from GI effects during space travel to combating severe dehydration in infants and optimizing sports performance, our journey over the past 15 years has been marked by groundbreaking research and development. This acquisition propels us further in our mission to create scientifically validated, IP-protected products that improve the quality of life for individuals worldwide. Join us as we embark on this exciting new chapter, advancing health and wellness through the transformative power of natural amino acids! #HealthcareInnovation #AmiLyfeBioscience #Bioscience #HealthAndWellness #Sustainability #Innovation
AmiLyfe BioScience LLC Acquires Entrinsic Bioscience LLC Assets, Unlocking Health & Wellness Through its Natural Amino Acid-based Health Products
prweb.com
-
Unlocking the next billion$$ in business value through Hybrid Cloud and AI. Committed to bridging the skills gap in underrepresented communities. Passionate about healthcare.
I am super excited on the prospect of #Google #AlphaFold3 impact on personalized medicine. AlphaFold 3, building on its previous version, can now predict the structures of not just proteins, but nearly all the key molecules in living organisms, including DNA, RNA, and even drug molecules. This is a game-changer for biology and medicine. Imagine having a digital twin of a patient's biology, where we can see how different treatments interact with their unique molecular makeup. This paves the way for personalized medicine at a whole new level. Here's how AlphaFold 3 and digital twins could revolutionize healthcare: Tailored treatment plans: ➡️ By simulating how a patient's specific molecules respond to different drugs, doctors can design personalized treatment plans with better efficacy and fewer side effects. ➡️ Accelerated drug discovery: AlphaFold 3 can analyze potential drug molecules and predict how they bind to target proteins, speeding up the drug development process. ➡️ New insights into disease: Understanding the 3D structure of all biological molecules can provide a deeper understanding of how diseases arise and progress. This is just the beginning of a new era in personalized medicine. AlphaFold 3, along with digital twins, holds immense promise for improving patient outcomes and creating a future of truly preventative healthcare. #AlphaFold #DigitalTwins #PersonalizedMedicine #Healthcare #FutureofScience https://lnkd.in/gzexrwEc
AlphaFold 3 predicts the structure and interactions of all of life’s molecules
blog.google
-
"Honored to have presented at the II Congress of BioMedLab on 'Biomarkers Development: From Exploratory Discovery to Clinical & Industry Impact'. Grateful for the invitation and impressed by the exceptional organization, speakers, and the massive turnout of 500 participants! A fantastic platform for advancing biomarker research. #BioMedLab #Biomarkers #Research #InnovativeClinicalTrials"
-
-
🎤 Cellino CEO & Co-Founder, Nabiha Saklayen, will be speaking at Demy-Colton’s #BioFuture2024 next week in #NYC! Join her and Susan Hockfield, President Emerita of Massachusetts Institute of Technology, for a Fireside Chat on "The Convergence of AI and Biomanufacturing: Pioneering the Future of Regenerative Medicine." Moderator Kimberly Ha, Founder & CEO of KKH Advisors, will lead the conversation as they discuss how #AI-driven breakthroughs in #biomanufacturing are transforming regenerative medicine. The discussion on Wednesday, October 30 will cover key topics such as: 🔷 The shift from traditional therapeutics to personalized cellular therapies 🔷 How living medicines derived from a patient’s own cells can potentially cure chronic diseases 🔷 Challenges and opportunities in scaling regenerative medicine for widespread use 🔷 Recent advancements in biomanufacturing for cell therapies Register and find us on the BioFuture™ meeting platform from October 28-30 to connect at the event or request a virtual one-to-one meeting: https://lnkd.in/gV-2q65m We’re excited to connect and discuss how we can collectively improve healthcare outcomes for all patients! 🚀 #DemyColton #Biotech #AI #MachineLearning #Innovation #RegenMed #Therapeutics #PersonalizedMedicine #FutureofHealthcare #YourCellsYourCure #CellinoBio
-
-
Imagine Biotech 𝐬𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧'𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 🚀 Promising discovery from our scientists for a 3rd party that could lead to new treatments for Parkinson's disease and other neurodegenerative conditions. 𝐓𝐡𝐞 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 🔬 - A compound, identified through cutting-edge AI and virtual screening, shows the potential to target and inhibit the A2A adenosine receptor. 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 🤔 - This receptor plays a key role in the development of Parkinson's disease. Inhibiting it could help alleviate symptoms and slow disease progression. 𝐓𝐡𝐞 𝐅𝐢𝐧𝐝𝐢𝐧𝐠 💡 - Our scientists found a compound that fits perfectly into a critical part of the receptor, potentially blocking its harmful effects. 𝐍𝐞𝐱𝐭 𝐒𝐭𝐞𝐩𝐬 🌎 - Further testing and experiments are needed to confirm the effectiveness and safety of this potential treatment. #biotech #science #biotechnology #therapeutics
-
-
How can we accelerate the delivery of innovative #health techniques and products to patients who need it? By working together to make cell, gene and tissue related therapies available to all European citizens! 💡 That’s why eight European organisations - including flanders.bio - joined forces in the European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB). By building a European interconnected value chain, the #EHAB will identify regional strengths, weaknesses, gaps and needs. 🇪🇺 Stay updated on our progress in strengthening the European landscape in Advanced Therapies and Biomaterials (AT&B) by following the EHAB page! ☝🏼 🫱🏽🫲🏾 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 BOM (Brabantse Ontwikkelings Maatschappij) (🇳🇱) - Brightlands Maastricht Health Campus (🇳🇱) - BioRegio STERN Management GmbH (🇩🇪) - A4TEC Association (🇵🇹) - Biocat, BioRegion of Catalonia (🇪🇸) - RISE Research Institutes of Sweden (🇸🇪) - MedSilesia Cluster - Silesian Medical Devices Network (🇵🇱) - flanders.bio (🇧🇪) 🙌🏽 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝗿𝘀 Provincie Noord-Brabant - Provincie Limburg - RegMed XB - Departement Economie, Wetenschap en Innovatie (EWI) - Vanguard Initiative - Generalitat de Catalunya - Leitat Technological Center - AseBio - Asociación Española de Bioempresas - Vall d'Hebron Institute of Oncology (VHIO) - Fraunhofer IPA. Funded by the European Union.
-
